| Date | Title | Description |
| 25.09.2024 | Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study | - Patients are preselected for CDKN2A and/or CDKN2B abnormalities -
- Safety and efficacy data to be reported at an upcoming oncology medical conference -
BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, ... |
| 04.09.2024 | Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference | BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 03.09.2024 | Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter | BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 14.08.2024 | Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update | - Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -
- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -
- Management to Host Conference Call at 4:30 pm EDT Today -
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLO... |
| 14.08.2024 | Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update | - Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well -
- 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 -
- Management to Host Conference Call at 4:30 pm EDT Today -
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLO... |
| 07.08.2024 | Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results | BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 14.05.2024 | Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update | - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -
- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study -
- Balance Sheet Bolstered w... |
| 02.05.2024 | Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules | BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on can... |
| 19.03.2024 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | – On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 –
– Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation –
– Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARC... |
| 13.03.2024 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results | BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 07.03.2024 | Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 | - |
| 06.03.2024 | Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit | - |
| 08.01.2024 | Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement | BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 09.08.2023 | Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update | - Key Catalysts ahead with Multiple Value Generating Readouts-
- Expects to Release Phase 1/2 Data with Oral Fadraciclib -
- Signals of Single-agent Efficacy with Oral Plogosertib -
- Management to Host Conference Call at 4:30 pm EDT Today-... |
| 03.08.2023 | Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results | BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 11.05.2023 | Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update | /EIN News/ -- - Key Catalysts ahead with multiple Value Generating Readouts -
- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -
- Advancing single-agent Efficacy with Differentiated Oral Plogosertib -
- Adds to Balance She... |
| 06.03.2023 | Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update | /EIN News/ -- - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 -
- Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation -
- Expect to Report Initial Data from Oral P... |
| 05.01.2023 | Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 | /EIN News/ -- – Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib –
– 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors –
– Expecting Key Data Readouts for Oral ... |
| 03.11.2022 | Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results | /EIN News/ -- BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicin... |
| 26.10.2022 | Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 | Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients
/EIN News/ -- BERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmace... |
| 26.10.2022 | Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 | BERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, repor... |
| 24.10.2022 | Cyclacel Hosting Research & Development Day | /EIN News/ -- -Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
-Monday, October 31st @ 10 am ET-
BERKELEY HEIGHTS, N.J., Oct. 24, 2022 (GLOB... |
| 24.10.2022 | Cyclacel Hosting Research & Development Day | -Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
-Monday, October 31st @ 10 am ET-
BERKELEY HEIGHTS, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) --... |
| 13.10.2022 | Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium | BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 21.09.2022 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference | BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 10.08.2022 | Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update | - Oral fadraciclib demonstrated good tolerability with continuous dosing;
anticipate entering Phase 2 POC stage in 2H 2022 –
- Demonstrated evidence of target engagement for CDK2 and CDK9 –
- Company to host R&D day in fall of 2022 to h... |
| 03.08.2022 | Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results | BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 30.06.2022 | Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline | - Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -
- No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date -
- Demonstrated Evidence of Target Engagement for CDK2 and CDK9 -
- Early ... |
| 11.05.2022 | Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update | - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 -
- First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and L... |
| 04.05.2022 | Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results | BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on can... |
| 19.04.2022 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas | BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 12.04.2022 | Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia | -New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia-
-Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion-
BERKELEY HEIGHTS, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- ... |
| 28.03.2022 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results | -Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –
-Cash Runway to Mid 2023-
-Conference Call Scheduled for March 28, 2022, at 4:30 p.m. EDT-
BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE... |
| 22.03.2022 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results | BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 07.02.2022 | Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference | BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 06.01.2022 | Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 | – Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
– Expecting Key Data Readouts for Oral Fadraciclib in 2022 –
– Planning to Launch Two Registration-Directed Studies for Differentiated Oral ... |
| 06.01.2022 | Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022 | – Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
– Expecting Key Data Readouts for Oral Fadraciclib in 2022 –
– Planning to Launch Two Registration-Directed Studies for Differentiated Oral ... |
| 23.12.2021 | Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference | BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 10.11.2021 | Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update | - Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -
- Cash Runway to Early 2023 -
- Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET -
BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Ph... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes | Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes | BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes | BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 29.10.2021 | Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update | BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 11.08.2021 | Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update | - Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -
- Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow -
- Cash Runway to Early 2023 -
- Conference Call Scheduled August 11, 2021 at 4:30 p.m. ... |
| 13.07.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas | BERKELEY HEIGHTS, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 15.03.2021 | Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference | BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 12.03.2021 | Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock | BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on c... |
| 26.02.2021 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results | BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on can... |
| 19.02.2021 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results | BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on ca... |
| 11.01.2021 | CYCLACEL PHARMACEUTICALS, INC.
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021 | – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–
– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –
– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures–
BE... |
| 04.05.2012 | Cancer drug developer Cyclacel raising $3 million | Research and development costs for the drug increased by 44 percent, or $2.8 million, to $9.2 million in 2011 over the previous year.
There are more than 11,900 new cases of acute myeloid leukemia diagnosed in the United States each year, m... |
| - | Cancer drug developer Cyclacel raising $3 million | Cyclacel Pharmaceuticals (NASDAQ:CYCC), a cancer drug developer, is raising $3 million for litigation expenses to protect its intellectual property, according to documents filed with the U.S. Securities Exchange Commission.
The financing wi... |
